As we continue to advance our commercial build, we are preparing for the future addition of field sales personnel to support our growing organization. In advance of formal job postings expected to go live in the coming months, we are beginning to identify and gather information from prospective candidates who meet our qualifications and may be interested in joining our Commercial team. The final number of sales positions and specific geographic territories are still being determined; however, engaging with interested candidates now will help streamline our recruiting efforts and allow us to more efficiently connect qualified individuals with relevant opportunities once positions are formally posted.
We are particularly interested in experienced oncology sales professionals with a demonstrated track record of strong performance, including experience launching oncology therapeutics for rare cancer subtypes and promoting oral oncology agents. If you are interested in being considered for future opportunities, please submit your resume and provide some baseline information about your experiences.
We strongly encourage you to monitor our Career Page for active postings and apply to roles that are a good match for your experience, skills, and interests.
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
